DelveInsight’s, “Adult-onset growth hormone deficiency - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Adult-onset growth hormone deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Adult-onset growth hormone deficiency Understanding
    Adult-onset growth hormone deficiency: Overview
    Adult-onset growth hormone deficiency is a medical condition that occurs when the pituitary gland in brain does not produce enough growth hormone. Most cases of adult-onset growth hormone deficiency result from damage to the pituitary gland caused by a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Adult-onset growth hormone deficiency is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves.

    "Adult-onset growth hormone deficiency - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adult-onset growth hormone deficiency pipeline landscape is provided which includes the disease overview and Adult-onset growth hormone deficiency treatment guidelines. The assessment part of the report embraces, in depth Adult-onset growth hormone deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adult-onset growth hormone deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Adult-onset growth hormone deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Adult-onset growth hormone deficiency.

    Adult-onset growth hormone deficiency Emerging Drugs Chapters
    This segment of the Adult-onset growth hormone deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Adult-onset growth hormone deficiency Emerging Drugs
    • Sogroya (somapacitan-beco): Novo Nordisk
    Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco. The drug is registered in USA for the treatment of growth hormone deficiency in adults.
    • TransCon hGH: Ascendis Pharma
    TransCon hGH is an investigational prodrug of somatropin (human growth hormone) in phase 3 development as a once-weekly therapy for children and adults with GHD. TransCon hGH has orphan designation for GHD in both the U.S. and Europe.
    Further product details are provided in the report??..

    Adult-onset growth hormone deficiency: Therapeutic Assessment
    This segment of the report provides insights about the different Adult-onset growth hormone deficiency drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Adult-onset growth hormone deficiency
    There are approx. 3+ key companies which are developing the therapies for Adult-onset growth hormone deficiency. The companies which have their Adult-onset growth hormone deficiency drug candidates in the mid to advanced stage, i.e. phase III include, Ascendis Pharma and others.

    Phases
    DelveInsight’s report covers around 3+ products under different phases of clinical development like
    • Late-stage products (Phase III)
    • Mid-stage products (Phase II and Phase I/II)
    • Early-stage products (Phase I/II and Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates

    Route of Administration
    Adult-onset growth hormone deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Subcutaneous
    • Intravenous
    • Oral
    • Intramuscular
    • Molecule Type

    Products have been categorized under various Molecule types such as
    • Small molecules
    • Natural metabolites
    • Monoclonal antibodies
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Adult-onset growth hormone deficiency: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adult-onset growth hormone deficiency therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult-onset growth hormone deficiency drugs.

    Adult-onset growth hormone deficiency Report Insights
    • Adult-onset growth hormone deficiency Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Adult-onset growth hormone deficiency Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Adult-onset growth hormone deficiency drugs?
    • How many Adult-onset growth hormone deficiency drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adult-onset growth hormone deficiency?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adult-onset growth hormone deficiency therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Adult-onset growth hormone deficiency and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Novo Nordisk
    • Ascendis Pharma

    Key Products
    • Sogroya
    • TransCon hGH